ExpreS2ion Biotech Holding
1.98 SEK
+0.51 %
Less than 1K followers
EXPRS2
First North Stockholm
Biotechnology & Pharmaceuticals
Health Care
Overview
Financials & Estimates
Ownership
Dividend
Investor consensus
+0.51 %
-20.90 %
-62.59 %
-65.22 %
-65.22 %
-70.99 %
-96.69 %
-99.52 %
-96.45 %
ExpreS2ion is a Danish-based biotech company listed in Sweden. The company develops a portfolio of vaccines for diseases such as COVID-19, influenza, and breast cancer through the use of its non-viral cell-based expression system, ExpreS2, which is recognized for handling protein challenges. ExpreS2ion has developed Expres2, which is a technology platform for efficient and fast non-clinical development and production of complex proteins for new vaccines and diagnostics. The company’s current primary product is the corona vaccine candidate, ABNCoV2 in phase 2, co-developed with its partner, AdaptVac of which ExpreS2ion owns 34%. The vaccine candidate has been licensed to Bavarian Nordic has global commercialization rights and responsibility for further clinical development of the vaccine and is expected to initiate phase 3 testing for the product candidate in the first half of 2022.
Read moreMarket cap
46.21M SEK
Turnover
69.69K SEK
Revenue
3.66M
EBIT %
-1,210.56 %
P/E
-
Dividend yield-%
-
Latest research
Latest analysis report
Released: 25.02.2026
Revenue and EBIT-%
Revenue M
EBIT-% (adj.)
EPS and dividend
EPS (adj.)
Dividend %
Financial calendar
28.5
2026
Interim report Q1'26
25.6
2026
General meeting '26
20.8
2026
Interim report Q2'26
All
Research
Webcasts
Press releases
ShowingAll content types
Dagens aktienyheder 05/05-2026: ISS, ALK-Abelló, Trifork, Rovsing og Expres2ion
ExpreS2ion announces final outcome of its rights issue of units
Join Inderes community
Don't miss out - create an account and get all the possible benefits
Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools
